{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-023851","form_type":"8-K","ticker":"ERAS","cik":"0001761918","company_name":"Erasca, Inc.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.025923+00:00","generated_at":"2026-06-22T01:42:36.573751+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Erasca Q3 2022 net loss $35.5M; cash $365.5M funds ops into H2 2024","bullets":["Net loss $35.5M ($0.29/sh) vs $46.1M ($0.46/sh) in Q3 2021; R&D spend $28.2M.","Cash, cash equivalents & marketable securities $365.5M as of Sep 30, 2022; expects to fund operations into H2 2024.","Positive preliminary monotherapy data for ERAS-007 and ERAS-601: 23% response in RAS/MAPK-altered non-CRC solid tumors.","Entered CTCSAs with Lilly (cetuximab + ERAS-601) and Pfizer (palbociclib + ERAS-007); strategic R&D collaboration with MD Anderson.","Upcoming milestones: IND for CNS-penetrant KRAS G12C inhibitor ERAS-3490 by year-end 2022; combo data for ERAS-007/601 in H1 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-023851","json":"https://secwatch.observer/filing/0000950170-22-023851.json","markdown":"https://secwatch.observer/filing/0000950170-22-023851.md","text":"https://secwatch.observer/filing/0000950170-22-023851.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/0000950170-22-023851-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/eras-20221109.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:42:36.573751+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ab9d0bc7be1529678b8f7b92d4aa0f9c5fdf9ce0","claim":"Erasca, Inc. reported financial results for the fiscal quarter ended September 30, 2022.","evidence_excerpt":"Erasca, Inc. announced its financial results for the quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1761918/000095017022023851/0000950170-22-023851-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}